Ani Pharmaceuticals, Inc. · NASDAQ:ANIP
Ani Pharmaceuticals — Q2 2023 Earnings Presentation
16 slides from Ani Pharmaceuticals's earnings presentation, Aug 30, 2023
Slide 1: Investor Presentation August 2023
© 2023 ANI Pharmaceuticals, Inc. 1 © 2023 ANI Pharmaceuticals, Inc. 1 Investor Presentation August 2023
Slide 2: Disclaimer
© 2023 ANI Pharmaceuticals, Inc. 2 Disclaimer This presentation by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) contains forward - looking statements, including informatio n about management's view of the Company’s future expectations, plans and prospects, as well as other forward - looking sta
Slide 3: ANI Pharmaceuticals Is Well Positioned to Drive Sustainable Profitable Growth
© 2023 ANI Pharmaceuticals, Inc. 3 ANI Pharmaceuticals Is Well Positioned to Drive Sustainable Profitable Growth Scaling up Rare Disease business with Purified Cortrophin Gel (PCG) launch momentum and adding assets that leverage our Rare Disease infrastructure Maximize value from Established Brands
Slide 4: 2022 Was a Landmark Year for ANI, and the Momentum Has Continued During the First Half of 2023
© 2023 ANI Pharmaceuticals, Inc. 4 2022 Was a Landmark Year for ANI, and the Momentum Has Continued During the First Half of 2023 (1) Adjusted non - GAAP EBITDA is a non - GAAP financial measure. For reconciliation of Adjusted Non - GAAP EBITDA to the most directly co mparable GAAP measure, please s
Slide 5: ANI Achieved Record Quarterly Revenues and Adjusted Non-GAAP EBITDA in Q1 2023, and Again in Q2 2023
© 2023 ANI Pharmaceuticals, Inc. 5 ANI Achieved Record Quarterly Revenues and Adjusted Non - GAAP EBITDA in Q1 2023, and Again in Q2 2023 Revenues ($ million) Adjusted Non - GAAP EBITDA (1) ($ million) $42 (1) Adjusted non - GAAP EBITDA is a non - GAAP financial measure. For reconciliation of Adjust
Slide 6: Raised Full Year 2023 Guidance for Second Quarter in a Row
© 2023 ANI Pharmaceuticals, Inc. 6 Raised Full Year 2023 Guidance for Second Quarter in a Row (1) Adjusted non - GAAP EBITDA and Adjusted Non - GAAP Diluted EPS are non - GAAP financial measures. For reconciliation to the most d irectly comparable GAAP measure, please see Appendix A. Metric ($ milli
Slide 7: Strong Launch Momentum for Foundational Rare Disease Asset, Purified Cortrophin Gel
© 2023 ANI Pharmaceuticals, Inc. 7 Strong Launch Momentum for Foundational Rare Disease Asset, Purified Cortrophin Gel Accelerating momentum with record number of new patient starts and new cases initiated, as well as continued increase in new unique prescribers in Q2’23 • Continued growth in repeat
Slide 8: ACTH Class Has Shown Year-over-Year Monthly Unit Growth For 13 consecutive months
© 2023 ANI Pharmaceuticals, Inc. 8 ACTH Class Has Shown Year - over - Year Monthly Unit Growth For 13 consecutive months Source: IQVIA ACTH Units – Year - over - Year Change From June 2022 to June 2023, the ACTH category has demonstrated thirteen months of consecutive growth year - over - year -12.0
Slide 9: Strong R&D capabilities, operational excellence and U.S.-based manufacturing footprint helped drive growth in Generics
© 2023 ANI Pharmaceuticals, Inc. 9 Strong R&D capabilities, operational excellence and U.S. - based manufacturing footprint helped capture new business opportunities and drive growth in Generics 1 Superior pipeline and new product launch execution • Increased R&D investment with focus on niche oppor
Slide 10: U.S. Based Manufacturing Footprint; Strong GMP Track Record, Including Successful Recent Audits at All Three Sites
© 2023 ANI Pharmaceuticals, Inc. 10 U.S. Based Manufacturing Footprint; Strong GMP Track Record, Including Successful Recent Audits at All Three Sites • Manufacturing, packaging, warehouse • Schedule CII vault & CIII cage space • Lab space - R&D/analytical testing • Solutions, suspensions, topicals,
Slide 11: Executive Leadership Team with Proven Track Records and Broad Industry Expertise
© 2023 ANI Pharmaceuticals, Inc. 11 Executive Leadership Team with Proven Track Records and Broad Industry Expertise ‒ 20+ years of legal and leadership experience in specialty and generics pharmaceuticals ‒ Served as Vice President and Associate GC for Amneal Pharmaceuticals ‒ Previously with Morga
Slide 12: ANI Pharmaceuticals Is Well Positioned to Drive Sustainable Profitable Growth
© 2023 ANI Pharmaceuticals, Inc. 12 ANI Pharmaceuticals Is Well Positioned to Drive Sustainable Profitable Growth Scaling up Rare Disease business with Purified Cortrophin Gel (PCG) launch momentum and adding assets that leverage our Rare Disease infrastructure Maximize value from Established Brands
Slide 13: ANI Recently Celebrated a Decade since Listing on the NASDAQ
© 2023 ANI Pharmaceuticals, Inc. 13 ANI Recently Celebrated a Decade since Listing on the NASDAQ
Slide 14: Appendix
© 2023 ANI Pharmaceuticals, Inc. 14 © 2023 ANI Pharmaceuticals, Inc. 14 Investor Presentation August 2023
Slide 15: Adjusted Non-GAAP EBITDA Calculation – 2Q 2023 and 22
© 2023 ANI Pharmaceuticals, Inc. 15 Adjusted Non - GAAP EBITDA Calculation – 2Q 2023 and 2022 Adjusted non-GAAP EBITDA Calculation and US GAAP to Non-GAAP Reconciliation (unaudited, in thousands) 2023 2022 Net Income (Loss) $ 6,245 $ (14,923) Add/(Subtract): Interest expense, net 7,100 6,669 Other e
Slide 16: Adjusted Non-GAAP EBITDA Calculation – Full Year 2022 and 2021
© 2023 ANI Pharmaceuticals, Inc. 16 Adjusted Non - GAAP EBITDA Calculation – Full Year 2022 and 2021 (1) Adjustment to other expense, net excludes $750K of income related to the sale of an ANDA during the three months ended December 31, 2021, and excludes $750K and $1.9 million of income related to